Skip to main content

IGF-1 LR3

Also known as: Long R3 IGF-I, Long R3 IGF-1, Long-(Arg3)-IGF-I, LR3IGF-I, LongR3-IGF-I

Classification

Peptide

Regulatory Status

not-established

Overview

IGF-1 LR3 (Long-Arg3-IGF-I) is a synthetic 83-amino-acid analogue of human IGF-1 bearing an arginine substitution at position 3 and a 13-amino-acid N-terminal extension; these modifications reduce its affinity for IGF-binding proteins, contributing to a longer functional half-life and greater potency than native IGF-1 in preclinical models. FDA's Substance Registration System assigns it UNII M9L22Y19H9 with CAS 143045-27-6; commercial vendor chemical listings commonly cite a different CAS number (946870-92-4) for the same substance name, an identifier discrepancy that is unresolved.

Evidence and limitations

Human/preclinical evidence breakdown is not available in this record.

Pathways

IGF-1 LR3 (Long-Arg3-IGF-I) is a synthetic 83-amino-acid analogue of human IGF-1 bearing an arginine substitution at position 3 and a 13-amino-acid N-terminal extension; these modifications reduce its affinity for IGF-binding proteins, contributing to a longer functional half-life and greater potency than native IGF-1 in preclinical models. FDA's Substance Registration System assigns it UNII M9L22Y19H9 with CAS 143045-27-6; commercial vendor chemical listings commonly cite a different CAS number (946870-92-4) for the same substance name, an identifier discrepancy that is unresolved.

Interactions & cautions

insulin or other hypoglycemic agents — Potential additive hypoglycemia risk (review)

These are observational flags for review, not individualized instructions.

Sources

Educational reference only — not medical advice.

IGF-1 LR3 Research & Evidence | BioStack